✦ LIBER ✦

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

✍ Scribed by Bixby, D.; Talpaz, M.

Book ID: 121715366
Publisher: American Society of Hematology
Year: 2009
Tongue: English
Weight: 280 KB
Volume: 2009
Category: Article
ISSN: 1520-4391
DOI: 10.1182/asheducation-2009.1.461

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SP 108 Resistance to tyrosine kinase inh

SP 108 Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

✍ T. Lion 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Novel therapeutic approach to eradicate

Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells

✍ Kazuhito Naka; Takayuki Hoshii; Atsushi Hirao 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 328 KB

Mutational Analysis and Overcoming Imati

Mutational Analysis and Overcoming Imatinib Resistance in Chronic Myeloid Leukemia with Novel Tyrosine Kinase Inhibitors

✍ Michael J. Mauro 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 155 KB

Mechanisms and novel approaches in overr

Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia

✍ Karvela, Maria ;Helgason, G Vignir ;Holyoake, Tessa L 📂 Article 📅 2012 🏛 Expert Reviews 🌐 English ⚖ 1009 KB

Allogeneic Stem Cell Transplantation for

Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia Resistant to Tyrosine Kinase Inhibitors

✍ Richard Champlin; Elias Jabbour; Partow Kebriaei; Paolo Anderlini; Borje Anderss 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 270 KB

Drug Resistance in Cancer Cells || Mecha

Drug Resistance in Cancer Cells || Mechanisms of Resistance to Targeted Tyrosine Kinase Inhibitors

✍ Siddik, Zahid H.; Mehta, Kapil 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 663 KB

It was estimated that in 2008, 1,437,180 patients would receive a new cancer diagnosisand 565,650individualswould die of cancer (Jemal et al. 2008).Since the vast majority of patients dying of cancer will have had anticancer therapy, both c- ventional chemotherapy and novel targeted therapy, it can